HCS Pharma shares should be listed on the Frankfurt stock exchange in the next six months. The company is launching a pre-IPO on the European Digital Asset Exchange (EDSX) that will allow investors to buy shares with a 20% discount on the final listing price. HCS Pharma has already raised more than €2 million with private sales and has recently opened the public sales: https://www.edsx.ch/projects/hcs-pharma The goal is to raise €7 million to strengthen its position as a developer of regenerative medicine and cellular therapy.
read more